Skip to main content

Advertisement

Log in

A randomized trial of intravitreal bevacizumab vs. ranibizumab for myopic CNV

  • Letter to the Editor
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Pece A, Milani P, Monteleone C, Trombetta CJ, De Crecchio G, Fasolino G, Matranga D, Cillino S, Vadalà M (2015) A randomized trial of intravitreal bevacizumab vs. ranibizumab for myopic CNV. Graefes Arch Clin Exp Ophthalmol 253:1867–1872. doi:10.1007/s00417-014-2886-x

    Article  CAS  PubMed  Google Scholar 

  2. Tan CS, Chew MC, Lim TH (2014) Comparison of foveal-sparing with foveal-involving photodynamic therapy for myopic choroidal neovascularization. Eye (Lond) 28:17–22. doi:10.1038/eye.2013.204

    Article  CAS  Google Scholar 

  3. Tan CS, Chew MC, Lim KH, Lim TH (2013) Factors affecting visual outcome of myopic choroidal neovascularization treated with verteporfin photodynamic therapy. Int J Ophthalmol 6:327–330. doi:10.3980/j.issn.2222-3959.2013.03.13

    PubMed  PubMed Central  Google Scholar 

  4. Maruko I, Iida T, Sugano Y, Saito M, Sekiryu T (2011) Subfoveal retinal and choroidal thickness after verteporfin photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol 151:594–603. doi:10.1016/j.ajo.2010.10.030, e1

    Article  CAS  PubMed  Google Scholar 

  5. Isola V, Pece A, Parodi MB (2006) Choroidal ischemia after photodynamic therapy with verteporfin for choroidal neovascularization. Am J Ophthalmol 142:680–683. doi:10.1016/j.ajo.2006.04.028

    Article  CAS  PubMed  Google Scholar 

  6. Lee PY, Kim KS, Lee WK (2009) Severe choroidal ischemia following photodynamic therapy for pigment epithelial detachment and chronic central serous chorioretinopathy. Jpn J Ophthalmol 53:52–56. doi:10.1007/s10384-008-0613-z

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Colin S. Tan.

Ethics declarations

Funding

Dr Tan receives research funding from the National Healthcare Group (Singapore) Clinician Scientist Career Scheme Grant (Code: CSCS/12005). Dr Tan also receives travel support from Bayer (South East Asia) Pte. Ltd., Heidelberg Engineering (Heidelberg, Germany), and Novartis (Singapore). These are not directly related to the subject matter or materials discussed in this manuscript. Dr Cheong, Dr Lim, and Mr Tan do not receive funding.

Conflict of interest

The authors report no conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tan, C.S., Cheong, K.X., Lim, L.W. et al. A randomized trial of intravitreal bevacizumab vs. ranibizumab for myopic CNV. Graefes Arch Clin Exp Ophthalmol 254, 1433–1434 (2016). https://doi.org/10.1007/s00417-016-3284-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-016-3284-3

Keywords

Navigation